Humacyte

NASDAQ: HUMA ↗$0.63 USD~$50M (post-June 2026 offering, mid-2026) MCAP

#Vascular Access for Dialysis #Regenerative Medicine #Bioengineered Human Tissues #Vascular Trauma Repair #Cardiovascular Surgery

Humacyte is a clinical-stage biotechnology company developing a pipeline of bioengineered human tissues and blood vessels using its proprietary LifePod platform and other regenerative-medicine manufacturing technologies. The lead product, ATEV (Acellular Tissue Engineered Vessel), is a first-in-class bioengineered blood vessel that has shown superiority in female dialysis-access patients in the V012 Phase 3 study (data June 2026), with a supplemental BLA filing planned in H2 2026. The company completed a 47.6M-share underwritten public offering in June 2026.

Company Info

Sector:Biotechnology / Regenerative Medicine (Bioengineered Tissues)

Headquarters:Durham, North Carolina, USA

Founded:2004

Website:www.humacyte.com/

Upcoming Milestones & Key Dates

H2 2026

Regulatory

Planned supplemental BLA filing for ATEV in dialysis vascular access

Q3 2026

Corporate

Q2 2026 financial results and post-offering cash-runway update

Clinical Development Pipeline

ATEV (SYMBVION)

Target: Bioengineered acellular human tissue vessel

Vascular access for end-stage renal disease / hemodialysis; V012 Phase 3 superiority readout positive in female dialysis-access patients (June 2026); supplemental BLA planned H2 2026

Preclinical

Phase 1

Phase 2

Phase 3

Approved

ATEV (Trauma / Vascular Injury)

Target: Bioengineered acellular human tissue vessel

Vascular injury and trauma repair

Preclinical

Phase 1

Phase 2

Phase 3

Approved

LifePod and other regenerative platforms

Target: Bioengineered tissue platforms

Preclinical — multiple regenerative medicine applications

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Laura Niklason, M.D., Ph.D.

Founder, President and Chief Executive Officer

Careers & Job Openings

See all open roles

Multiple Departments

Durham, NC

Apply Now →